{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:07:01Z","timestamp":1787317621732,"version":"build-2736575974"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"05","funder":[{"name":"Sanofi-Aventis Deutschland GmbH finanziert"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gesundheitswesen"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Hintergrund Die Rheumatoide Arthritis (RA) ist eine chronisch\n                    entz\u00fcndliche systemische Auto-immunerkrankung mit destruierenden\n                    Gelenkver\u00e4nderungen und progredientem Verlauf. Daten zur\n                    Pr\u00e4valenz bei erwachsenen Patienten sind in Deutschland nur\n                    eingeschr\u00e4nkt verf\u00fcgbar.<\/jats:p>\n                  <jats:p>Methodik Es wurden anonymisierte Diagnose- und Verordnungsdaten aus den\n                    Jahren 2008\u20132013 auf Patientenebene f\u00fcr ca. 2,3 Mio. erwachsene\n                    Versicherte (Gesamtdatensatz; Stand 2013) bzw. ca. 1,2 Mio. erwachsene\n                    Versicherte (kleinerer Datensatz mit Zusatzinformationen wie Behandlung durch\n                    einen Facharzt; Stand 2013) von 7 verschiedenen gesetzlichen\n                    Krankenversicherungen ausgewertet. Die Diagnose RA wurde vergeben, wenn die\n                    Kodierung M05 (seropositive chronische Polyarthritis) bzw. M06 (sonstige\n                    chronische Polyarthritis) vorlag (Diagnosegruppe M0[5,6]) und innerhalb eines\n                    Kalenderjahres entweder mindestens 2-mal ambulant (in 2 verschiedenen Quartalen)\n                    oder mindestens einmal station\u00e4r gestellt wurde (entsprechend der\n                    BVA-Kriterien werden also station\u00e4re Diagnosen als verl\u00e4sslicher\n                    eingestuft). Die Daten wurden auf die GKV-Versicherten und\n                    Gesamtbev\u00f6lkerung in Deutschland f\u00fcr das Jahr 2013\n                    hochgerechnet.<\/jats:p>\n                  <jats:p>Ergebnisse Die Pr\u00e4valenz der RA im Gesamtdatensatz lag bei\n                    durchschnittlich 1,26% \u00fcber alle Jahre hinweg\n                    (2008\u20132013). Die Diagnose beruht dabei zu \u00fcber 90% auf\n                    dem Diagnoseschl\u00fcssel M06. Die Einstufung basiert in 88% der\n                    F\u00e4lle ausschlie\u00dflich auf ambulanten Diagnosen. Unter\n                    Ber\u00fccksichtigung einer Diagnosestellung durch einen Facharzt\n                    (Facharztkriterium) auf Basis eines kleineren Datensatzes, der diese\n                    Zusatzinformation enth\u00e4lt, zur Bestimmung einer\n                    \u201esicheren\u201c RA-Diagnose, lag die mittlere RA-Rate f\u00fcr die\n                    Jahre 2011\u20132013 bei etwa 0,99%. Bezogen auf die Diagnosegruppe\n                    M0[5,6] im Gesamtdatensatz lag die Pr\u00e4valenz der RA im Jahr 2013 bei\n                    etwa 1,8% der Frauen, und bei etwa 0,8% der M\u00e4nner. Nur\n                    rund 40% der diagnostizierten Patienten wurden mit DMARDs behandelt.<\/jats:p>\n                  <jats:p>Schlussfolgerungen Die aus dem gr\u00f6\u00dferen Datensatz\n                    abgeleiteten Pr\u00e4valenzsch\u00e4tzungen f\u00fcr RA entsprechen\n                    denen fr\u00fcherer Erhebungen mit teilweise anderen methodischen\n                    Ans\u00e4tzen. Basierend auf der vorgelegten Analyse der Krankenkassendaten\n                    betr\u00e4gt die Pr\u00e4valenz der diagnostizierten RA bei Erwachsenen in\n                    Deutschland 1,26% und liegt damit innerhalb der Spanne von\n                    0,81\u20131,62%, die der Literatur zu entnehmen ist. Dies entspricht\n                    einer Zahl von rund 721\u2009000 erwachsenen GKV-Versicherten. Die niedrige\n                    Rate der DMARD-Verschreibungen kann auf eine Unterversorgung dieser Patienten\n                    hindeuten.<\/jats:p>","DOI":"10.1055\/a-1192-4628","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T19:25:48Z","timestamp":1598642748000},"page":"367-373","source":"Crossref","is-referenced-by-count":12,"title":["Pr\u00e4valenz der Rheumatoiden Arthritis in Deutschland: Analyse\n                    von L\u00e4ngsschnittdaten der Gesetzlichen\n                    Krankenversicherung"],"prefix":"10.1055","volume":"83","author":[{"given":"Carsten","family":"Kienitz","sequence":"additional","affiliation":[{"name":"EbM\/ HEOR, Sanofi-Aventis Deutschland GmbH Berlin,\n                    Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Grellmann","sequence":"additional","affiliation":[{"name":"Team Analytik, Gesundheitsforen Leipzig GmbH, Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Hapfelmeier","sequence":"additional","affiliation":[{"name":"Standort M\u00fcnchen, Vilua Healthcare GmbH,\n                    M\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"J S Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid\n                    Arthritis","volume":"68","author":"J A Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-018-8672-5","article-title":"Sex and Management of Rheumatoid Arthritis","volume":"56","author":"E G Favalli","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1477-7525-9-99","article-title":"Measurement properties of physical function scales validated for use in patients\n                    with rheumatoid arthritis: a systematic review of the literature","volume":"9","author":"M A Oude Voshaar","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10067-015-3071-2","article-title":"Validation and relevance of Rheumatoid Arthritis Pain Scale (RAPS) in Indian\n                    (Asian) patients suffering from rheumatoid arthritis","volume":"35","author":"T Kianifard","year":"2016","journal-title":"Clin Rheumatol"},{"key":"ref6","first-page":"1174","article-title":"Patient perspective: fatigue as a recommended patient centered outcome measure\n                    in rheumatoid arthritis","volume":"34","author":"J R Kirwan","year":"2007","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36:\n                    a systematic review and meta-analysis","volume":"44","author":"F Matcham","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/RHU.0000000000000489","article-title":"Systematic Review and Meta-analysis of Interventions for Depression and Anxiety\n                    in Persons With Rheumatoid Arthritis","volume":"23","author":"K M Fiest","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and\n                    implications","volume":"361","author":"B R England","year":"2018","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic\n                    and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"J S Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref11","first-page":"54","article-title":"Arbeitsgruppe Erhebung und Nutzung von Sekund\u00e4rdaten der Deutschen\n                    Gesellschaft f\u00fcr Sozialmedizin und Pr\u00e4vention, Arbeitsgruppe\n                    Epidemiologische Methoden der Deutschen Gesellschaft f\u00fcr Epidemiologie,\n                    Deutsche Gesellschaft f\u00fcr Medizinische Informatik Biometrie und\n                    Epidemiologie, Deutsche Gesellschaft f\u00fcr Sozialmedizin und\n                    Pr\u00e4vention. Good practice of secondary data analysis, first revision\n                    [original in German]","volume":"70","year":"2008","journal-title":"Gesundheitswesen"},{"issue":"S 01","key":"ref12","first-page":"e161","article-title":"A Consensus German Reporting Standard for Secondary Data Analyses, Version 2\n                    (STROSA-STandardisierte BerichtsROutine fur SekundardatenAnalysen)","volume":"78","author":"E Swart","year":"2016","journal-title":"Gesundheitswesen"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00393-016-0094-2","article-title":"Wie haufig sind muskuloskeletale Erkrankungen in Deutschland?","volume":"75","author":"A Zink","year":"2016","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00393-016-0088-0","article-title":"Pravalenz der rheumatoiden Arthritis in Deutschland auf Basis von Kassendaten:\n                    Regionale Unterschiede und erste Ergebnisse der PROCLAIR-Studie","volume":"75","author":"S Hense","year":"2016","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/03009748909092611","article-title":"Activity and severity of rheumatoid arthritis in Hannover\/FRG and in one\n                    regional referral center","volume":"79","author":"A Wasmus","year":"1989","journal-title":"Scand J Rheumatol Suppl"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the\n                    United States. Part I","volume":"58","author":"C G Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","article-title":"The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for\n                    a new century","volume":"41","author":"D Symmons","year":"2002","journal-title":"Rheumatology"},{"key":"ref19","first-page":"7","article-title":"Entz\u00fcndlich-rheumatische Erkrankungen","volume":"49","author":"A Zink","year":"2010","journal-title":"Gesundheitsberichterstattung des Bundes"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jbspin.2016.07.007","article-title":"Time trends in the incidence, prevalence, and severity of rheumatoid arthritis:\n                    A systematic literature review","volume":"83","author":"E Minichiello","year":"2016","journal-title":"Joint, bone, spine: revue du rhumatisme"}],"container-title":["Das Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1192-4628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T18:35:22Z","timestamp":1620844522000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1192-4628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":19,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2021,5,12]]},"published-print":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1192-4628","relation":{},"ISSN":["0941-3790","1439-4421"],"issn-type":[{"value":"0941-3790","type":"print"},{"value":"1439-4421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}